Sonoma Pharmaceuticals
SNOA
9 hedge funds and large institutions have $54.2K invested in Sonoma Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.57% less ownership
Funds ownership: 2.07% → 1.5% (-0.57%)
36% less funds holding
Funds holding: 14 → 9 (-5)
36% less capital invested
Capital invested by funds: $85.2K → $54.2K (-$31.1K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$13.2K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
-$31.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.88K |
| 3 |
Citigroup
New York
|
-$553 |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$82 |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $46.9K | +$13.2K | +4,700 | +37% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $6.47K | -$4.88K | -1,734 | -42% |
|
3
JP Morgan Chase
New York
| $371 | – | – | – |
|
4
BlackRock
New York
| $304 | – | – | – |
|
5
US Bancorp
Minneapolis,
Minnesota
| $67 | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $32 | +$25 | +9 | +300% |
|
7
Morgan Stanley
New York
| $11 | – | – | – |
|
|
AF
8
Allworth Financial
Folsom,
California
| $8 | – | – | – |
|
|
DB
9
Danske Bank
Copenhagen K,
Denmark
| $3 | – | – | – |
|
|
GSC
10
Ground Swell Capital
Folly Beach,
South Carolina
| – | -$31.9K | -10,400 | Closed |
|
|
11
Citigroup
New York
| – | -$553 | -180 | Closed |
|
|
12
Osaic Holdings
Scottsdale,
Arizona
| – | -$82 | -27 | Closed |
|
|
13
Wells Fargo
San Francisco,
California
| – | -$3 | -1 | Closed |
|
SNOA Hedge Fund Activity: Q4 2024 in Review
9 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q4 2024, worth a combined $54.2K — down 36% from $85.2K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SNOA and 0 opened new positions — a net loss of 5 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $13.2K. The largest seller was Ground Swell Capital, exiting entirely with an estimated $31.9K sold.
- 9 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q4 2024, down from 14 in Q3 2024.
- Funds reported $54.2K of Sonoma Pharmaceuticals stock for Q4 2024, down 36% quarter-over-quarter.
- 0 funds opened new Sonoma Pharmaceuticals positions in Q4 2024 and 5 closed out, a net change of -5 holders.
- The largest Sonoma Pharmaceuticals buyer in Q4 2024 was UBS Group, an estimated $13.2K added.
- The largest Sonoma Pharmaceuticals seller in Q4 2024 was Ground Swell Capital, an estimated $31.9K sold.
Based on aggregated 13F filings for Q4 2024.